High-intensity focused ultrasound (HIFU) is widely applied to tumors in clinical practice due to its minimally invasive approach. However, several issues lower therapeutic efficiency in some cases. Many synergists such as microbubbles and perfluorocarbon nanoparticles have recently been used to improve HIFU treatment efficiency, but none were determined to be effective and safe in vivo. In this study, nanoscale bubble-generating liposomes (liposomes containing ammonium bicarbonate [Lip-ABC]) were prepared by film hydration followed by sequential extrusion. Their stable nanoscale particle diameter was confirmed, and their bubble-generating capacity after HIFU triggering was demonstrated with ultrasound imaging. Lip-ABC had good stability in vivo and accumulated in the tumor interstitial space based on the enhanced permeability and retention effect evaluated by photoacoustic imaging. When used to synergize HIFU ablation to bovine liver in vitro and implanted breast tumors of BALB/c nude mice, Lip-ABC outperformed the control. Importantly, all mice survived HIFU treatment, suggesting that Lip-ABC is a safe HIFU synergist.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500488 | PMC |
http://dx.doi.org/10.2147/IJN.S135391 | DOI Listing |
World J Urol
March 2025
Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA.
Purpose: Despite the growing adoption of HIFU treatment for localized prostate cancer (PC), standardized criteria for evaluating success and predicting recurrence remain undefined. Herein, we analyze the predictive value of noninvasive tools such as PSA dynamics and MRI to determine recurrence.
Methods: We identified from our HIFU therapy prospective registry patients who developed biopsy-proven recurrence, between 2016 and 2023.
J Palliat Med
March 2025
MemorialCare Health System, Fountain Valley, California, USA.
The integration of palliative care into the U.S. health care system has grown significantly, with outpatient palliative care services (OPCSs) playing an increasingly vital role in managing patients with serious illnesses.
View Article and Find Full Text PDFRadiol Med
March 2025
Department of Nuclear Medicine, University Hospital Bonn, University of Bonn, NRW, Venusberg-Campus 1, 53127, Bonn, Germany.
Objectives: Uterine fibroids often lead to symptoms that negatively impact health-related quality of life (HRQOL). High-intensity focused ultrasound (HIFU) has emerged as a promising noninvasive treatment for reducing fibroid size and symptoms. The Mirabilis system for ultrasound (US)-guided HIFU introduces a novel technique known as 'shell ablation'.
View Article and Find Full Text PDFTremor Other Hyperkinet Mov (N Y)
March 2025
Department of Neurology, Consorci Sanitari de Terrassa, Barcelona, Spain.
Background: Essential tremor (ET) presents therapeutic challenges as oral therapies, are often partially effective and carry adverse effects. Deep Brain Stimulation and High-intensity Focused Ultrasound targeting the ventral intermediate thalamic nucleus show efficacy in managing ET; however, their cost and invasiveness deter some patients. Botulinum toxin infiltrations for ET in the upper limbs have been limited by adverse effects.
View Article and Find Full Text PDFEur J Radiol
March 2025
Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. Electronic address:
Purpose: To validate the TARGET score for multiparametric MRI (mpMRI) following high-intensity focused ultrasound (HIFU) therapy and to compare its diagnostic performance to the PI-FAB score.
Methods: This IRB-approved retrospective, single-center study included 83 patients who underwent follow-up mpMRIs and subsequent prostate biopsies at 6, 12, and 36 months after HIFU therapy for localized prostate cancer (05/2014-10/2021). Two radiologists independently assessed TARGET and PI-FAB scores.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!